Acrivon (ACRV): יתרות המזומנים של החברה

לוגו גרפי של Acrivon Therapeutics (ACRV)

Acrivon Therapeutics (ACRV) creates personalized tumor treatments leveraging predictive diagnostics and capital support. The company is implementing the APAM AI system to develop targeted inhibitors, demonstrating significant scientific potential. A breakthrough in AP3 precision proteomics and the preparation of CHK1/2 releases are transforming diagnostics. The cash-on-hand metric illustrates the balance between liquidity and capital efficiency, where 0.08 shows the current value of the metric.

יתרות המזומנים של החברה: Acrivon (ACRV) עבור 28.04.2023 - 21.11.2026

ACRV (Acrivon): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- ציטוטים ותחזית אנליסטים:
ניתוח כל מדדי החברה:Acrivon Pharma
פריט של המותג Acrivon Therapeutics Inc

For the biotech startup Acrivon Therapeutics (ACRV), which lacks revenue and depends on clinical trial results, its liquidity cushion serves as the primary guarantee of survival. The current cash on hand stands at 0.08, allowing for a real-time assessment of the business's discounted value and a comparison of existing financial reserves against market capitalization to determine the level of downside protection for the capital.